ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed … – GlobeNewswire (press release)
|
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
GlobeNewswire (press release) “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |
|
MPEG LA invites CRISPR-Cas9 patents to be pooled in a one-stop license
BSI bureau (press release) Pooling the foundational CRISPR patent rights under a single nonexclusive, cost-effective, transparent license will allow the market to focus on the creation of new products and therapies that accelerate and expand CRISPR’s deployment. Just as MPEG LA … |
|
MPEG LA invites CRISPR-Cas9 patents to be pooled in a one-stop license
BSI bureau (press release) Pooling the foundational CRISPR patent rights under a single nonexclusive, cost-effective, transparent license will allow the market to focus on the creation of new products and therapies that accelerate and expand CRISPR’s deployment. Just as MPEG LA … |
|
Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR–T cells patents
Yahoo Finance The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T–Cells that are engineered to be T–Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). |
|
Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR–T Cells Patents
Business Wire (press release) Celyad (Paris:CYAD) (Brussels:CYAD), a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR–T cells. This license … |
News-Medical.net |
Noninvasive PET imaging may predict cancer patients’ immunotherapy response early
News-Medical.net Response to immunotherapy often cannot be measured effectively at early time points by traditional imaging techniques that measure tumor size, such as CT and MRI scans, or those that measure tumor glucose uptake, such as FDG PET, because these … Granzyme B Probe Plus PET Scanning Helps Determine Response To ImmunotherapyMedicalResearch.com (blog) |